Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trialJan B. Vermorken, Herbert M. Pinedo, Renate Ezinga et al.|The Lancet|1999Cited by 503
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialJan B. Vermorken, Bruce Allen Bach|The Lancet Oncology|2013Cited by 433
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H. Machiels, Ezra E.W. Cohen, Robert I. Haddad et al.|The Lancet Oncology|2015Cited by 394
Taxanes: A New Class of Antitumor AgentsManon Huizing, Jos H. Beijnen, Vinoj H Sewberath Misser et al.|Cancer Investigation|1995Cited by 283
Paclitaxel-induced neuropathyT.J. Postma, J.J. Heimans, Jan B. Vermorken et al.|Annals of Oncology|1995Cited by 270